10.7 Management of Neonatal Jaundice

1. Scope and Core Bedside Rules

Bedside Rule	How to Apply It
Population	Infants ≥35 weeks: use the AAP 2022 age-in-hours, gestational-age, and neurotoxicity-risk-factor thresholds. Infants <35 weeks: use local NICU consensus thresholds or institutional nomograms, with lower tolerance for rapid rise, hemolysis, sepsis, acidosis, hypoalbuminemia, or instability.
Measurement principle	Use total serum bilirubin (TSB) for treatment decisions when close to threshold, during phototherapy, during escalation, in the first 24 hours, and in infants <35 weeks. TcB is a screening tool, not a definitive treatment value.
Do not subtract direct bilirubin	Use the total bilirubin value when applying phototherapy or exchange thresholds. A high direct/conjugated fraction should trigger cholestasis evaluation but should not be subtracted when assessing acute bilirubin neurotoxicity risk.
Jaundice in first 24 hours	Treat as pathologic until proven otherwise. Measure serum bilirubin urgently, assess hemolysis, and repeat frequently until the value is below threshold and stable or falling.
Management priority	When TSB is close to exchange level or there are signs of acute bilirubin encephalopathy, start intensive phototherapy immediately while preparing transfer and/or exchange transfusion. Do not wait for all laboratory results.

2. Immediate Triage: Which Pathway Does the Baby Need?

Clinical Situation	Management Pathway
Well baby, ≥35 weeks, no prior phototherapy	Plot TSB or TcB against age in hours using the AAP 2022 framework. Decide phototherapy, discharge timing, and repeat bilirubin based on distance from the phototherapy threshold.
Visible jaundice <24 hours	Urgent serum bilirubin within 2 hours; evaluate maternal and infant blood type, DAT, CBC/reticulocytes, and hemolysis risk. Repeat TSB every 4–6 hours or sooner if rapid rise.
Baby on phototherapy	Confirm device irradiance, expose maximum skin area, use TSB not TcB. Repeat TSB 4–6 hours after starting, then every 6–12 hours once stable or falling.
Near exchange threshold	Escalation pathway: NICU-level care, intensive phototherapy, hydration/feeding plan, urgent labs, blood bank notification, neonatology/hematology consultation, and transfer if exchange not available at current unit.
Signs of acute bilirubin encephalopathy	Emergency — do not wait for thresholds. Start intensive phototherapy, prepare exchange transfusion, secure IV access, check glucose/electrolytes/calcium, and involve a senior neonatologist immediately.
Conjugated hyperbilirubinemia or pale stool / dark urine	Not physiologic jaundice. Continue acute neurotoxicity assessment using total bilirubin, but initiate cholestasis/liver-disease workup and urgent GI/hepatology referral when indicated.

3. Before Treatment: Minimum Data Needed

Before choosing a treatment threshold, document gestational age, postnatal age in hours, birth weight/current weight, clinical condition, feeding adequacy, neurotoxicity risk factors, bilirubin method, and the bilirubin value used for decision-making.

Domain	Action
Bilirubin	TSB; direct/conjugated bilirubin if pathologic jaundice; TcB only for screening when appropriate.
Hemolysis screen	Maternal ABO/Rh and antibody screen; infant ABO/Rh; DAT; CBC; reticulocyte count; smear; and rate of TSB rise.
Binding risk	Albumin if TSB is close to escalation/exchange threshold, the infant is ill, or exchange transfusion is being considered.
G6PD	Check when ancestry or family history suggests risk, jaundice is severe or unexplained, TSB rises despite intensive phototherapy, or escalation of care is needed.
Illness screen	Evaluate for sepsis, acidosis, hypoxia, hypothermia/temperature instability, poor intake/dehydration, and other contributors that lower neurotoxicity tolerance.
Prolonged jaundice	Measure total and direct bilirubin. Investigate cholestasis, hypothyroidism, galactosemia, infection/UTI when clinically suspected, liver disease, and hemolysis.

Neurotoxicity risk factors that lower treatment thresholds

Use lower-risk tolerance when any of the following are present: gestational age <38 weeks, isoimmune hemolytic disease, G6PD deficiency or other hemolysis, sepsis or clinical instability, significant acidosis, low albumin, lethargy or evolving encephalopathy, or a rapidly rising bilirubin.

4. Phototherapy

Phototherapy is the first-line treatment for significant unconjugated hyperbilirubinemia. It works only when enough skin surface receives effective blue light at adequate irradiance.

Phototherapy Step	Practical Instruction
When to start	Use the appropriate age-in-hours and gestational-age threshold. For infants ≥35 weeks, use AAP 2022 thresholds. For <35 weeks, use institutional preterm thresholds and senior review.
Type	Use LED, fiberoptic, or fluorescent phototherapy with an effective blue-light spectrum. For severe jaundice, use intensive phototherapy with overhead high-intensity light plus underbody fiberoptic pad when available.
Irradiance target	For intensive phototherapy, aim for high irradiance over the maximum body surface area. Baylor uses an intensive target of at least 30 µW/cm²/nm; verify device output regularly.
Positioning	Maximize exposed skin while maintaining thermoregulation. Keep the infant supine unless a clinical reason prevents it. Avoid barriers such as thick blankets or non-approved covers.
Eye and skin care	Use eye protection according to unit policy, check position regularly, and monitor skin temperature, hydration, stooling, and device distance from the infant.
Monitoring TSB	Repeat TSB 4–6 hours after starting phototherapy, then every 6–12 hours if stable/falling. Repeat sooner when hemolysis, rapid rise, or escalation concern is present.
Feeding	Support breastfeeding and enteral feeding. Do not give water or dextrose water for jaundice. If intake is poor or weight loss is excessive, use expressed breast milk, donor milk, formula, or IV fluids according to clinical status.
Stopping	For infants ≥35 weeks, stop when sufficiently below the phototherapy threshold and rebound risk is acceptable. NICE stops when TSB is at least 50 µmol/L below the threshold; Baylor notes healthy term infants often stop around 13–14 mg/dL when clinically appropriate.
Rebound check	Check rebound bilirubin when hemolysis is present, phototherapy was started early, infant is preterm, or TSB was close to threshold. NICE recommends 12–18 hours after stopping; AAP timing depends on risk category.

Common phototherapy failures — fix these before escalating unnecessarily

The bilirubin value was TcB rather than TSB.
The infant was not undressed enough or phototherapy was interrupted frequently.
The light source was too far away or irradiance was not verified.
Hemolysis, G6PD deficiency, sepsis, dehydration, or acidosis was missed.
The direct bilirubin was incorrectly subtracted from total bilirubin.
A sick preterm infant was managed using a term-infant threshold.

5. Escalation of Care

Escalation is time-sensitive

Escalation should begin before bilirubin reaches exchange level when the trajectory suggests possible exchange transfusion. Do not wait for the final threshold to be crossed.

Escalation Domain	Required Action
Trigger	TSB at or near escalation threshold; rapidly rising bilirubin despite intensive phototherapy; suspected hemolysis with poor response; or any sign of acute bilirubin encephalopathy.
Immediate actions	Move to NICU/high-acuity area; start or verify intensive phototherapy; notify senior neonatologist; call blood bank early.
Monitoring	Continuous cardiorespiratory and temperature monitoring; repeat TSB every 2 hours until clearly falling and below escalation concern.
Laboratories	TSB/direct bilirubin, CBC, reticulocyte count, DAT, blood type, albumin, glucose, electrolytes, calcium, blood gas if ill, G6PD if indicated, and sepsis tests if clinically suspected.
Access	Secure reliable IV access and prepare umbilical venous access if exchange may be needed. Do not delay treatment while access plans are being finalized.
Consults / transfer	If exchange transfusion cannot be performed promptly in the current unit, transfer early while intensive phototherapy continues during transport whenever feasible. Baylor Ed. 33 (Ch 18.6): preparing blood for exchange almost always takes 4–6 hours, so factor that in. Call the exchange centre if any of: TSB ≥17 mg/dL with haematocrit <35% (severe haemolysis); TSB within 2–3 mg/dL of the exchange level despite 4–6 h of intensive phototherapy and IVIG; TSB rising more than 0.5–1 mg/dL per hour despite intensive phototherapy; or a B/A ratio reaching 6.5 (≥38 weeks), 6 (35–36 6/7 weeks and well, or ≥38 weeks with higher risk, isoimmune disease or G6PD deficiency) or 5.5 (35–36 6/7 weeks with higher risk, isoimmune disease or G6PD deficiency).
Family communication	Explain that the goal is to prevent acute bilirubin encephalopathy and that preparation for exchange may be needed even if exchange is ultimately avoided.

6. Intravenous Immunoglobulin (IVIG)

IVIG is not routine jaundice therapy

It is a selective adjunct for immune-mediated hemolysis when bilirubin is rising despite optimized intensive phototherapy and exchange risk is approaching.

IVIG Question	Guideline Answer
Best candidate	DAT-positive isoimmune hemolytic disease (Rh, ABO, or other red-cell antibody) with TSB reaching escalation concern or rising rapidly despite intensive phototherapy.
Dose range	Common neonatal dose is 0.5–1 g/kg IV over 2–4 hours; some protocols allow a repeat dose after 12 hours if bilirubin continues to rise. Follow local blood-product/immunoglobulin policy.
Before giving	Confirm intensive phototherapy is optimized; review risk of NEC/volume load; discuss with senior neonatologist and hematology/transfusion medicine when possible; and do not delay exchange preparation.
Avoid routine use	Do not use IVIG for non-immune jaundice, physiologic jaundice, breast milk jaundice, or mild DAT positivity without a dangerous bilirubin rise.
After giving	Continue intensive phototherapy and repeat TSB frequently. If TSB reaches exchange threshold or neurologic signs appear, proceed to exchange despite IVIG.

7. Exchange Transfusion

Bilirubin-to-albumin ratio — the second number in the exchange decision (Baylor Ed. 33 / AAP 2022)

When the TSB is at or approaching the exchange threshold, measure serum albumin and calculate the B/A ratio (TSB in mg/dL ÷ albumin in g/dL) as an additional factor. Blood for exchange is modified whole blood — red cells plus plasma — cross-matched against the mother and compatible with the infant; send for immediate type and crossmatch as the level approaches.

Risk category	B/A ratio at which exchange should be considered
≥38 0/7 weeks without neurotoxicity risk factors	8.0
35 0/7–37 6/7 weeks without risk factors, or ≥38 0/7 weeks with risk factors	7.2
35 0/7–37 6/7 weeks with risk factors	6.8

Exchange immediately, regardless of the curve

If the infant shows signs of acute bilirubin encephalopathy — hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry — or the TSB is ≥5 mg/dL above the exchange line, exchange immediately. For a readmitted infant whose TSB is above the exchange level, repeat the TSB every 2–3 hours and proceed to exchange if it remains above the line after 6 hours of intensive phototherapy. The dashed portion of the AAP curve in the first 24 hours reflects genuine uncertainty across a wide range of clinical circumstances — use judgement there, not the line.

Preterm infants below 35 weeks — the AAP curves do not apply

There are no AAP recommendations for LBW, VLBW or ELBW infants. Baylor uses consensus thresholds derived from controlled trials and expert opinion. Use birth weight, not the infant's current weight, when reading this table; for SGA and LGA infants consider using the 50th percentile weight for gestational age instead. Use lower values in a sick infant — acidosis, sepsis, haemolytic disease, hypoalbuminaemia.

Birth weight	Phototherapy — TSB (mg/dL) to start				Exchange transfusion
Birth weight	<24 h	24–48 h	48–72 h	72–168 h	Exchange transfusion
<750 g	≥5				>13
750–999 g	≥5		≥7		>15
1000–1499 g	5–7	7–9	10–12		15–16
1500–1999 g	5–8	8–10	10–12	13–15	16–18
2000–2500 g	5–8	8–11	11–13	13–15	18–19

Baylor Table 8-6. The source also gives a second-week column (14–15 mg/dL at 2000–2500 g). In VLBW infants, measure TSB at 24 hours and daily for the first few days, per the VLBW care chapter.

Ordering and running the exchange — the operational detail

Order blood as the equivalent of whole blood and ask the blood bank to mix packed red cells and plasma to a haematocrit of 40%.
Volume: a double-volume exchange is the most efficient. Blood required = 90 mL/kg × body weight × 2, plus 30–50 mL to prime the tubing.
Access: the #8 French catheter from the exchange set, filled with heparinized saline, into the umbilical vein. Aim the tip at the level of the right diaphragm; if that cannot be reached, advance only far enough for free flow on gentle suction. Confirm position radiographically and secure at the umbilicus.
Routine albumin priming before exchange is not indicated, and routine calcium salts during the exchange are not recommended.
Running it: prime the system fully and exhaust all air first. Turn the stopcock clockwise only. Exchange in 5–20 mL increments by size and condition, documenting volume in and out for each pass, with vital signs every 15–30 minutes. Most double-volume exchanges take 1 to 1.5 hours.
Environment: radiant warmer, ECG monitoring, a means of measuring blood pressure, a nurse dedicated to continuous assistance and documentation, and oxygen, suction and resuscitation equipment immediately to hand.
Afterwards: monitor vital signs closely for 2 hours, and send CBC, TSB, calcium and electrolytes. Do not send a repeat ABO type or neonatal profile unless the blood bank asks for one.

Uncommon but lifesaving

Exchange transfusion is now rare but remains lifesaving when bilirubin neurotoxicity risk is high or when acute bilirubin encephalopathy is suspected. Do not stop phototherapy at any point while preparing for exchange.

Exchange Step	Practical Instruction
Indications	Acute bilirubin encephalopathy at any TSB; TSB at/above exchange threshold; failure of intensive phototherapy during escalation; or severe hemolytic disease with ongoing rise.
Do while preparing	Continue intensive phototherapy. Do not stop phototherapy while waiting for blood, consent, line placement, or transport.
Blood product	Use institution-specific exchange blood. Belize describes fresh type O Rh-negative irradiated packed RBCs resuspended in AB plasma, crossmatched against maternal plasma/cells. Local blood bank policy must define the final product.
Volume	Double-volume exchange typically replaces about 85% of circulating red cells. Use local calculation based on estimated blood volume, weight, hematocrit, and circuit/tubing volume.
Aliquots	Use small aliquots — usually no more than about 10% of blood volume per cycle; monitor hemodynamics, calcium, glucose, potassium, acid-base status, and temperature throughout.
Post-exchange	Resume intensive phototherapy; check TSB at 2, 4, and 6 hours or per local protocol; repeat CBC/electrolytes/calcium/glucose; and monitor for rebound.
Complications	Thrombocytopenia, hypocalcemia, hypoglycemia or hyperglycemia, electrolyte disturbance, acidosis/alkalosis, arrhythmia, catheter complications, portal vein thrombosis, NEC, infection, and transfusion reactions.

8. Readmitted Infant With Severe Jaundice

Step	Action
First hour	Assess neurologic status, hydration, weight loss, feeding history, stool/urine color, temperature, and sepsis signs. Obtain TSB/direct bilirubin and start intensive phototherapy immediately if threshold met.
Labs	TSB/direct bilirubin; CBC with smear; reticulocyte count; maternal and infant blood type; DAT; albumin; G6PD if indicated; and sepsis/urine evaluation when clinical features suggest infection.
Feeding / hydration	Breastfeed or bottle feed every 2–3 hours when safe. Use expressed milk or formula supplementation if intake is inadequate. Use IV fluids when dehydration, poor perfusion, vomiting, or unsafe oral intake is present.
Escalation	If TSB is very high, rising, or within exchange range, notify blood bank and transport/exchange center early. Phototherapy should continue during transfer when feasible.
Discharge after readmission	Discharge only when TSB is safely below threshold, rebound risk is addressed, feeding/weight trajectory is safe, and follow-up bilirubin or clinical visit is scheduled.

9. Discharge and Follow-Up After Phototherapy

Discharge Domain	Required Plan
Risk at stopping	Assess age at phototherapy start, hemolysis, gestational age, current TSB relative to treatment threshold, feeding adequacy, weight loss, and family ability to return promptly.
Rebound bilirubin	Check rebound according to risk. Earlier and more reliable follow-up is needed after early phototherapy (<24–48 hr), immune hemolysis, G6PD deficiency, prematurity, or stopping close to threshold.
Follow-up timing	For infants ≥35 weeks, AAP follow-up is based on the difference between measured bilirubin and the phototherapy threshold, plus clinical risk factors. NICU preterm infants require individualized follow-up planning.
Hemolytic disease	Check discharge hemoglobin and bilirubin. Arrange late-anemia monitoring — commonly around 2 weeks, then based on rate of Hb fall — especially after IUT, IVIG, or exchange.
Parent teaching	Teach parents to return for poor feeding, lethargy, worsening jaundice, fever/temperature instability, dark urine, pale stool, fewer wet diapers, or abnormal tone/cry.

10. Special Populations and High-Risk Situations

Situation	Management Emphasis
Infants <35 weeks	Use preterm-specific NICU thresholds or institutional consensus charts. Lower treatment tolerance is appropriate with lower gestational age, illness, acidosis, low albumin, sepsis, or hemolysis.
DAT-positive hemolysis	Monitor TSB rise closely. Consider IVIG only when immune hemolysis is clinically significant and bilirubin is rising despite intensive phototherapy near escalation/exchange levels.
G6PD deficiency	Think of G6PD when bilirubin rises suddenly, fails to fall with phototherapy, rebounds unexpectedly, or when ancestry/family history suggests risk. Avoid oxidative triggers.
Breastfeeding with suboptimal intake	Do not blame breast milk automatically. Assess latch, transfer, weight loss, stooling, urine output, and hydration. Use lactation support and medically indicated supplementation.
Conjugated hyperbilirubinemia	Direct bilirubin elevation is pathologic. Treat acute total bilirubin risk if present, but evaluate cholestasis and urgent biliary atresia/liver disease warning signs.
Skin color limitations	Visual jaundice assessment is less reliable in darker skin. Examine sclerae and gums, and use bilirubin measurement when jaundice is suspected regardless of skin appearance.

11. Source Integration Notes

Source	How It Was Used
Baylor 2025–2026	Provides the chapter backbone: AAP 2022 framework, phototherapy equipment/irradiance (intensive target ≥30 µW/cm²/nm), follow-up by distance from threshold, escalation concepts, and management summary.
West Midlands 2025–2028	Adds practical blood-group incompatibility monitoring, NICE threshold approach, do-not-subtract-direct-bilirubin rule, IVIG escalation, and late-anemia follow-up after hemolytic disease.
Belize 2018–2021	Adds useful workup detail, readmission labs, preterm treatment awareness, and exchange transfusion logistics (product composition, volume, monitoring). Some threshold figures are older and should be superseded by current AAP/NICE/local thresholds.
AAP 2022 + NICE CG98	AAP 2022 is the main reference for infants ≥35 weeks. NICE CG98 (updated October 2023) is the current UK reference for bilirubin measurement rules, visual assessment limits, phototherapy practice, prolonged jaundice, and threshold graphs.

12. Bedside Checklist

Before every treatment decision — verify all of these

Confirm gestational age and exact age in hours before applying any threshold.
Use TSB for treatment decisions; do not use TcB once treatment or escalation is being considered.
Do not subtract direct/conjugated bilirubin from total bilirubin for acute treatment decisions.
Start intensive phototherapy immediately when near exchange level; prepare exchange in parallel.
Look for hemolysis early: maternal antibodies, DAT, blood types, CBC, reticulocytes, smear, and rate of rise.
Check G6PD when jaundice is severe, unexplained, or poorly responsive to phototherapy.
Support feeding; avoid water or dextrose water as jaundice treatment.
Plan rebound bilirubin and follow-up based on hemolysis risk, gestational age, and distance from threshold.
For pale stool, dark urine, green jaundice, or persistent jaundice: evaluate conjugated hyperbilirubinemia urgently.
Document threshold used, bilirubin value, risk factors, treatment start/stop times, irradiance/device setup, and follow-up plan.

Key Takeaways — Chapter 10.7

Start phototherapy based on age-in-hours + gestational age + neurotoxicity risk factors — never on bilirubin number alone without context.
Intensive phototherapy means maximum skin exposure + verified irradiance ≥30 µW/cm²/nm with overhead + underbody light when available.
TSB is the gold standard for all treatment decisions; TcB is screening only. Do not subtract the conjugated fraction.
Escalation starts before the exchange threshold is hit — the trajectory matters as much as the absolute value.
Never stop phototherapy while waiting for exchange preparation, blood bank confirmation, or transport.
IVIG 0.5–1 g/kg is appropriate only for confirmed or strongly suspected immune hemolysis with a dangerous TSB rise; it does not replace exchange when exchange criteria are met.
Exchange transfusion is rare but lifesaving; use double-volume exchange with local blood bank product and monitor calcium, glucose, potassium, and hemodynamics per-cycle.
Rebound bilirubin should be planned for all infants with hemolysis, prematurity, early phototherapy, or stopping close to threshold.
Late anemia after hemolytic disease, IUT, IVIG, or exchange is real — arrange discharge Hb and scheduled outpatient Hb monitoring.
Always involve lactation support before blaming breastfeeding; poor intake is treatable and usually avoidable with early skilled help.

References and Key Source Links

Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026. Section 8.5: Management of Neonatal Jaundice.
West Midlands Neonatal Operational Delivery Network. Neonatal Guidelines 2025–2028. Jaundice, Blood Group Incompatibilities, and Exchange Transfusion guidance.
Belize Ministry of Health. Neonatal Clinical Practice Guidelines 2018–2021. Neonatal Jaundice and Exchange Transfusion sections.
Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859.
American Academy of Pediatrics. Technical Report: Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058865.
National Institute for Health and Care Excellence. Jaundice in newborn babies under 28 days. Clinical Guideline CG98. Last updated 31 October 2023. https://www.nice.org.uk/guidance/cg98

Clinical governance note

This is an educational guideline synthesis. Use local hour-specific, gestation-specific bilirubin charts, local blood bank policies, and institutional neonatal thresholds for patient care decisions.